Mucormycosis is a fungal infection caused by exposure to mucormycetes molds which are common in the environment. It mainly affects those with health problems or medicines that lower the immune system. There are several types but it most commonly infects the sinuses or lungs. Symptoms vary depending on location but may include facial swelling, fever, cough, or skin lesions. Those at highest risk include diabetics, cancer patients, and those with organ or stem cell transplants or prolonged steroid use. Diagnosis involves tissue biopsy and imaging tests. Treatment involves controlling risk factors, surgery to remove infected areas, and antifungal medication like liposomal amphotericin B. Prevention focuses on managing diabetes and

1. Mucormycosis
Presented by;
Dr. Mithun G. Maniyar
M Pharm Ph.D.

2. Introduction
Mucormycosis (previously called zygomycosis)
It is caused by a group of molds called mucormycetes. These
molds live throughout the environment.
Mucormycosis mainly affects people who have health
problems or take medicines that lower the body’s ability to
fight germs and sickness.
It most commonly affects the sinuses or the lungs after
inhaling fungal spores from the air.

3. Types of Mucormycosis:
Rhinocerebral (sinus and brain) mucormycosis is an infection in the sinuses that can spread to the brain. This
form of mucormycosis is most common in people with uncontrolled diabetes and in people who have had a
kidney transplant.
Pulmonary (lung) mucormycosis is the most common type of mucormycosis in people with cancer and in
people who have had an organ transplant or a stem cell transplant.
Gastrointestinal mucormycosis is more common among young children than adults, especially premature and
low birth weight infants less than 1 month of age, who have had antibiotics, surgery, or medications that lower
the body’s ability to fight germs and sickness.
Cutaneous (skin) mucormycosis: occurs after the fungi enter the body through a break in the skin (for
example, after surgery, a burn, or other type of skin trauma). This is the most common form of mucormycosis
among people who do not have weakened immune systems.
Disseminated mucormycosis occurs when the infection spreads through the bloodstream to affect another
part of the body. The infection most commonly affects the brain, but also can affect other organs such as the
spleen, heart, and skin.

4. Symptoms
Rhinocerebral (sinus and brain)
mucormycosis include:
• One-sided facial swelling
• Headache
• Nasal or sinus congestion
• Black lesions on nasal bridge or upper inside
of mouth that quickly become more severe
• Fever
Pulmonary (lung) mucormycosis include:
• Fever
• Cough
• Chest pain
• Shortness of breath
Cutaneous (skin) mucormycosis
• Blisters or ulcers, and the infected area may
turn black. Pain
• Warmth
• Excessive redness
• Swelling around a wound.
Gastrointestinal mucormycosis include:
• Abdominal pain
• Nausea and vomiting
• Gastrointestinal bleeding
Disseminated mucormycosis Patients with
disseminated infection in the brain can
develop mental status changes or coma.

5. Who gets mucormycosis?
Mucormycosis is rare, but it’s more common among people who have health
problems or take medicines that lower the body’s ability to fight germs and
sickness. Certain groups of people are more likely to get mucormycosis,
including people with:
•Diabetes, especially with diabetic ketoacidosis
•Cancer
•Organ and Stem cell transplant
•Neutropenia (low number of white blood cells)
•Long-term corticosteroid use
•Injection drug use
•Too much iron in the body (iron overload or hemochromatosis)
•Skin injury due to surgery, burns, or wounds
•Prematurity and low birthweight (for neonatal gastrointestinal mucormycosis)

6. HOW TO DIAGNOSE MUCORMYCOSIS
Rhino-orbito-cerebral:
Endoscopic collection of debrided tissue/biopsy
Pulmonary
CT guided biopsy from lung
Chest X-ray and/or HRCT
Repeated negative galactomannan & beta-D- glucan tests

7. Treatment
1. Control of diabetes & diabetic ketoacidosis
2. Reduce steroids (if patient is still on) with aim to discontinue
rapidly
3. Discontinue other immunomodulating drugs if patient is taking
like: Baricitinib, Tofacitinib
4. Surgical debridement: Extensive, to remove all necrotic material;
if eye involved, exenteration of eye; in pulmonary, if the lesion is
localized or in one lobe.

8. 5. Medical treatment
a. Insert peripherally inserted central catheter (PICC line) or central
venous catheter
b. Maintain adequate systemic hydration, infuse normal saline IV before
amphotericin B infusion
c. Antifungal therapy
• Liposomal amphotericin B (L-AmB) (preferred treatment) 5mg/kg/day, dilute
in 200 cc 5% dextrose over 2-3 hours infusion (avoid slow escalation; higher
dose 10mg/Kg/day may be given in brain involvement)
• Amphotericin B deoxycholate (D-AmB): only if cost and availability of L-AmB
is an issue; 1mg/kg/day in 5% dextrose, slow infusion for 6-8 hours. Pre-
medication may be required to avoid infusion reaction.
• Monitor renal function & potassium level while treating with amphotericin B.

9. HOW TO PREVENT THIS INFECTION?
• As poorly controlled diabetes is the major issue, good glycemic
control is required
• Systemic steroids should only be used in patients with hypoxemia
• Oral steroids are contra indicated in patients with normal oxygen
saturation on room air
• If systemic steroid is used, blood sugar should be monitored
• The dose and duration of steroid therapy should be limited to
dexamethasone (0.1mg/kg/day) for 5-10 days
• During discharge, advice about the early symptoms or signs of
mucormycosis (facial pain, nasal blockage and excessive discharge,
loosening of teeth etc., chest pain, respiratory insufficiency)

10. MISINFORMATION & MISLEADING
• Mucorales are not black fungi
• Black fungi are different category of fungi having melanin in the
cell wall.
• Mucormycosis is not contagious. It does not spread from one
person to another.
• Mucormycosis is not spread by oxygenation, humidifier, and
water. The fungi remain in the indoor & outdoor environment. The
spores enter the respiratory tract via air.
• No antifungal prophylaxis is recommended as the incidence is not
more than 10% in any COVID-19 cohort.

11. Interesting fact

12. Thank you